Q1 2025 Abbott Laboratories Earnings Call Transcript
Key Points
- Abbott Laboratories (ABT) achieved high single-digit sales growth and double-digit earnings per share growth in the first quarter of 2025.
- The company's nutrition segment saw a 7% increase in sales, driven by high-single-digit growth in adult nutrition and double-digit growth in US pediatric nutrition.
- Medical devices sales grew 12.5%, with notable growth in diabetes care, electrophysiology, and structural heart segments.
- Abbott Laboratories (ABT) expanded its gross margin by 140 basis points and operating margin by 130 basis points compared to the prior year.
- The company is on track to launch more than 25 key new products over the next three years, indicating a strong pipeline for future growth.
- Sales in the diagnostics segment declined by 5% due to a year-over-year decline in COVID-19 testing sales.
- The company faces financial impacts from new tariff policies, with an estimated tariff impact of a few hundred million dollars in 2025.
- Foreign exchange had an unfavorable year-over-year impact of 2.8% on first-quarter sales.
- Volume-based procurement programs in China negatively impacted core laboratory diagnostics growth.
- The company is navigating challenges in the Chinese market due to price-driven volume-based procurement programs, which have not resulted in volume offsets.
Good morning and thank you for standing by. Welcome to Abbott's first-quarter 2025 earnings conference call. (Operator Instructions) This call is being recorded by Abbott. With the exception of any participants' questions asked during the question-and-answer session, the entire call, including the question-and-answer session, is material copyrighted by Abbott. It cannot be recorded or rebroadcast without Abbott's express written permission. I would now like to introduce Mr. Mike Comilla, Vice President, Investor Relations.
Good morning, everyone and thank you for joining us. With me today are Robert Ford, Chairman and Chief Executive Officer; and Phil Boudreau, Executive Vice President, Finance, and Chief Financial Officer. Robert and Phil will provide opening remarks. Following their comments, we'll take your questions.
Before we get started, some statements made today may be forward-looking for purposes of the Private Securities Litigation Reform Act of 1995, including the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
